https://ehaweb.org/congress/eha2023-hybrid-congress/program/program-by-day/ 6月8日,星期四: 6月9日,星期五 6月10日,星期六 6月11日,星期日
The EHA2023 Hybrid registration fee includes: Full Scientific program accessin Frankfurt, Germany and on the Congress platform from June 8-11, 2023, including the Invited Speaker Program and the Sponsored session program such as the Satellite Symposia Day on Thursday, June 8 and Updates-in-Hematol...
2023 EHA 第28届欧洲血液学学会年会(EHA2023 Hybrid Congress)将于2023年6月8-11日在德国法兰克福以线上和线下相结合的形式举办,会议由欧洲血液学学会(European Hematology Association)主办,每年吸引近万名来自世界各地的血液学专业人士参会,是血液...
2023年第28届欧洲血液学大会/年会(EHA2023 Hybrid Congress)于2023年6月8日至11日在德国法兰克福举行,会议由欧洲血液学会(EHA)举办。EHA大会是全球血液学领域规模最大的国际会议之一,涵盖了血液学研究的各个方面主题,分享探讨有关血液学的创新理念及最新的科学和临床研究成果。北京大学人民医院发布了一项关于超高灵敏N...
Welcome to the Congress Mobile App of the EHA2023 Hybrid Congress. The European Hematology Association promotes excellence in patient care, research, and education in hematology. EHA serves medical professionals, researchers, and scientists with an active interest in hematology and is proud to be the...
Welcome to the Congress Mobile App of the EHA2023 Hybrid Congress. The European Hematology Association promotes excellence in patient care, research, and education in hematology. EHA serves medical professionals, researchers, and scientists with an active interest in hematology and is proud to be the...
Notable Labs, Inc. today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – ...
[1] https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ [2] Thieblemont C, et al. J Clin Oncol. 2022;JCO2201725. [3] Iacoboni G, et al. Cancer Med. 2021;10(10):3214-3223. [4] 王方策, 等. 中华内科杂志, 2023,62(6):581-586. ...
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass mehrere Abstracts zu Daten aus seinem Onkologie-Portfolio beim anstehenden Jahrestreffen 2023 der American Society of Clinical Oncology (ASCO) vom 2. bis 6. Juni in Chicago und beim Hybrid Congress der European...
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation Clinical activity across indicati...